The cAMP effector EPAC activates Elk1 transcription factor in prostate smooth muscle, and is a minor regulator of α1-adrenergic contraction

Journal of Biomedical Science

Christian Gratzke¹  Christian G Stief¹  Sebastian Walther¹  Beata Rutz¹  Henning Schmetkamp¹  Frank Strittmatter¹  Martin Hennenberg¹ 

[1] Department of Urology, Ludwig-Maximilians University, Munich, Germany

关键词: Lower urinary tract symptoms (LUTS);    Bladder outlet obstruction (BOO);    Benign prostate obstruction (BPO);    Benign prostate hyperplasia (BPH);    Elk1;    EPAC;    Cyclic adenosin-3^′,5^′-monophosphate;    Smooth muscle relaxation;    Smooth muscle contraction;    α1-adrenoceptor;   

Others  :  823739
DOI  :  10.1186/1423-0127-20-46

 received in 2013-04-03, accepted in 2013-06-19,  发布年份 2013

【 摘 要 】

Background

Prostate smooth muscle tone is regulated by α1-adrenoceptor-induced contraction and cAMP-mediated relaxation. EPAC is an effector of cAMP, being involved in smooth muscle relaxation and cell cycle control outside the lower urinary tract. Here, we investigated the expression and function of EPAC in human prostate tissues from patients undergoing radical prostatectomy.

Results

mRNA and protein expression of EPAC was detected in all prostate tissues by RT-PCR and Western blot analysis. Immunoreactivity was observed in stromal cells, and colocalized with immunofluorescence for α-smooth muscle actin and calponin. Under normal conditions, noradrenaline- or phenylephrine-induced contraction of prostate strips in the organ bath was not affected by the EPAC activator pCPT (SP-8-pCPT-2^′-O-Me-cAMPS.NA) (30 μM). However, when the cyclooxygenase inhibitor indomethacin (50 μM) was added, EPAC activators pCPT and OME (8-CPT-2^′-O-Me-cAMP.Na) (30 μM) significantly reduced contractions by low concentrations of phenylephrine. These effects were not observed on noradrenaline-induced contraction. OME and pCPT caused phosphorylation of the transcription factor Elk1 in prostate tissues. Elk1 activation was confirmed by EMSA (electrophoretic mobility shift assay), where OME and pCPT incresed Elk1 binding to a specific DNA probe.

Conclusions

EPAC activation may reduce α1-adrenergic prostate contraction in the human prostate, although this effect is masked by cyclooxygenases and β-adrenoceptors. A main EPAC function in the human prostate may be the regulation of the transcription factor Elk1.

【 授权许可】

   
2013 Hennenberg et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

【 参考文献 】

• [1]Waldkirch E, Uckert S, Sigl K, et al.: Expression of cAMP-dependent protein kinase isoforms in the human prostate: functional significance and relation to PDE4. Urology 2010, 76:515 e8-14.
• [2]Drescher P, Eckert RE, Madsen PO: Smooth muscle contractility in prostatic hyperplasia: role of cyclic adenosine monophosphate. Prostate 1994, 25:76-80.
• [3]Kurokawa Y, Kojima K, Kanayama H, Kagawa S, Minami K, Nakaya Y: Activation of the Ca2+−activated K+ channel via protein kinase A-dependent phosphorylation in human prostatic smooth muscle cells. Int J Urol 1998, 5:482-486.
• [4]Michel MC, Vrydag W: Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol 2006, 147(Suppl 2):S88-S119.
• [5]Yamada S, Ito Y: alpha(1)-Adrenoceptors in the urinary tract. Handb Exp Pharmacol 2011, 202:283-306.
• [6]Michel MC: Beta-adrenergic receptor subtypes in the urinary tract. Handb Exp Pharmacol 2011, 202:307-318.
• [7]Andersson KE, Lepor H, Wyllie MG: Prostatic alpha 1-adrenoceptors and uroselectivity. Prostate 1997, 30:202-215.
• [8]Andersson KE, Gratzke C: Pharmacology of alpha1-adrenoceptor antagonists in the lower urinary tract and central nervous system. Nat Clin Pract Urol 2007, 4:368-378.
• [9]Roehrborn CG, Schwinn DA: Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol 2004, 171:1029-1035.
• [10]Andersson KE: LUTS treatment: future treatment options. Neurourol Urodyn 2007, 26:934-947.
• [11]Breckler M, Berthouze M, Laurent AC, Crozatier B, Morel E, Lezoualc’h F: Rap-linked cAMP signaling Epac proteins: compartmentation, functioning and disease implications. Cell Signal 2011, 23:1257-1266.
• [12]Bos CL, Richel DJ, Ritsema T, Peppelenbosch MP, Versteeg HH: Prostanoids and prostanoid receptors in signal transduction. Int J Biochem Cell Biol 2004, 36:1187-1205.
• [13]Gloerich M, Bos JL: Epac: defining a new mechanism for cAMP action. Annu Rev Pharmacol Toxicol 2010, 50:355-375.
• [14]Roscioni SS, Dekkers BG, Prins AG, et al.: cAMP inhibits modulation of airway smooth muscle phenotype via the exchange protein activated by cAMP (Epac) and protein kinase A. Br J Pharmacol 2011, 162:193-209.
• [15]Roscioni SS, Prins AG, Elzinga CR, et al.: Protein kinase A and the exchange protein directly activated by cAMP (Epac) modulate phenotype plasticity in human airway smooth muscle. Br J Pharmacol 2011, 164:958-969.
• [16]Roscioni SS, Maarsingh H, Elzinga CR, et al.: Epac as a novel effector of airway smooth muscle relaxation. J Cell Mol Med 2011, 15:1551-1563.
• [17]Sands WA, Palmer TM: Regulating gene transcription in response to cyclic AMP elevation. Cell Signal 2008, 20:460-466.
• [18]Francis H, Franchitto A, Ueno Y, et al.: H3 histamine receptor agonist inhibits biliary growth of BDL rats by downregulation of the cAMP-dependent PKA/ERK1/2/ELK-1 pathway. Lab Invest 2007, 87:473-487.
• [19]Mancinelli R, Onori P, Gaudio E, et al.: Follicle-stimulating hormone increases cholangiocyte proliferation by an autocrine mechanism via cAMP-dependent phosphorylation of ERK1/2 and Elk-1. Am J Physiol Gastrointest Liver Physiol 2009, 297:G11-G26.
• [20]Choe ES, Wang JQ: Group I metabotropic glutamate receptor activation increases phosphorylation of cAMP response element-binding protein, Elk-1, and extracellular signal-regulated kinases in rat dorsal striatum. Brain Res Mol Brain Res 2001, 94:75-84.
• [21]Choe ES, McGinty JF: N-Methyl-D-aspartate receptors and p38 mitogen-activated protein kinase are required for cAMP-dependent cyclase response element binding protein and Elk-1 phosphorylation in the striatum. Neuroscience 2000, 101:607-617.
• [22]Choe ES, McGinty JF: Cyclic AMP and mitogen-activated protein kinases are required for glutamate-dependent cyclic AMP response element binding protein and Elk-1 phosphorylation in the dorsal striatum in vivo. J Neurochem 2001, 76:401-412.
• [23]Vossler MR, Yao H, York RD, Pan MG, Rim CS, Stork PJ: cAMP activates MAP kinase and Elk-1 through a B-Raf- and Rap1-dependent pathway. Cell 1997, 89:73-82.
• [24]Metrich M, Morel E, Berthouze M, et al.: Functional characterization of the cAMP-binding proteins Epac in cardiac myocytes. Pharmacol Rep 2009, 61:146-153.
• [25]Schmidt M, Sand C, Jakobs KH, Michel MC, Weernink PA: Epac and the cardiovascular system. Curr Opin Pharmacol 2007, 7:193-200.
• [26]Lucia MS, Lambert JR: Growth factors in benign prostatic hyperplasia: basic science implications. Curr Urol Rep 2008, 9:272-278.
• [27]Timms BG, Hofkamp LE: Prostate development and growth in benign prostatic hyperplasia. Differentiation 2011, 82:173-183.
• [28]Strittmatter F, Walther S, Roosen A, et al.: Activation of protein kinase B/Akt by alpha1-adrenoceptors in the human prostate. Life Sci 2012, 90:446-453.
• [29]Shaikhibrahim Z, Lindstrot A, Ellinger J, et al.: The peripheral zone of the prostate is more prone to tumor development than the transitional zone: is the ETS family the key? Mol Med Report. 2012, 5(2):313-316.
• [30]Pradidarcheep W, Wallner C, Dabhoiwala NF, Lamers WH: Anatomy and histology of the lower urinary tract. Handb Exp Pharmacol 2011, 202:117-148.
• [31]Hennenberg M, Miersch J, Rutz B, et al.: Noradrenaline induces binding of Clathrin light chain A to alpha1-adrenoceptors in the human prostate. Prostate 2013, 73:715-723.
• [32]Grandoch M, Roscioni SS, Schmidt M: The role of Epac proteins, novel cAMP mediators, in the regulation of immune, lung and neuronal function. Br J Pharmacol 2010, 159:265-284.
• [33]Bos JL: Epac proteins: multi-purpose cAMP targets. Trends Biochem Sci 2006, 31:680-686.
• [34]Orsted DD, Bojesen SE: The link between benign prostatic hyperplasia and prostate cancer. Nat Rev Urol 2013, 10:49-54.
• [35]Alcaraz A, Hammerer P, Tubaro A, Schroder FH, Castro R: Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review. Eur Urol 2009, 55:864-873.
• [36]Beavo JA, Brunton LL: Cyclic nucleotide research – still expanding after half a century. Nat Rev Mol Cell Biol 2002, 3:710-718.
• [37]Buchwalter G, Gross C, Wasylyk B: Ets ternary complex transcription factors. Gene 2004, 324:1-14.
• [38]Shaw PE, Saxton J: Ternary complex factors: prime nuclear targets for mitogen-activated protein kinases. Int J Biochem Cell Biol 2003, 35:1210-1226.
• [39]Cohen-Armon M: PARP-1 activation in the ERK signaling pathway. Trends Pharmacol Sci 2007, 28:556-560.
• [40]Kawai-Kowase K, Owens GK: Multiple repressor pathways contribute to phenotypic switching of vascular smooth muscle cells. Am J Physiol Cell Physiol 2007, 292:C59-C69.
• [41]MacDonald JA: Smooth muscle phenotypic plasticity in mechanical obstruction of the small intestine. Neurogastroenterol Motil 2008, 20:737-740.
• [42]Xiao D, Qu X, Weber HC: GRP receptor-mediated immediate early gene expression and transcription factor Elk-1 activation in prostate cancer cells. Regul Pept 2002, 109:141-148.
• [43]Tyagi A, Agarwal R, Agarwal C: Grape seed extract inhibits EGF-induced and constitutively active mitogenic signaling but activates JNK in human prostate carcinoma DU145 cells: possible role in antiproliferation and apoptosis. Oncogene 2003, 22:1302-1316.
• [44]Grandoch M, Rose A, ter Braak M, et al.: Epac inhibits migration and proliferation of human prostate carcinoma cells. Br J Cancer 2009, 101:2038-2042.
• [45]Misra UK, Pizzo SV: Epac1-induced cellular proliferation in prostate cancer cells is mediated by B-Raf/ERK and mTOR signaling cascades. J Cell Biochem 2009, 108:998-1011.
• [46]Fang Y, Olah ME: Cyclic AMP-dependent, protein kinase A-independent activation of extracellular signal-regulated kinase 1/2 following adenosine receptor stimulation in human umbilical vein endothelial cells: role of exchange protein activated by cAMP 1 (Epac1). J Pharmacol Exp Ther 2007, 322:1189-1200.
• [47]Misra UK, Pizzo SV: Coordinate regulation of forskolin-induced cellular proliferation in macrophages by protein kinase A/cAMP-response element-binding protein (CREB) and Epac1-Rap1 signaling: effects of silencing CREB gene expression on Akt activation. J Biol Chem 2005, 280:38276-38289.
• [48]Hochbaum D, Hong K, Barila G, Ribeiro-Neto F, Altschuler DL: Epac, in synergy with cAMP-dependent protein kinase (PKA), is required for cAMP-mediated mitogenesis. J Biol Chem 2008, 283:4464-4468.
• [49]Fujita T, Meguro T, Fukuyama R, Nakamuta H, Koida M: New signaling pathway for parathyroid hormone and cyclic AMP action on extracellular-regulated kinase and cell proliferation in bone cells. Checkpoint of modulation by cyclic AMP. J Biol Chem 2002, 277:22191-22200.